Alvotech (ALVO) investor relations material

Recent commercial and pipeline developments

• Launched biosimilar Humira in 2024 and Stelara in February 2025, with additional biosimilars filed for approval including SIMPONI ARIA, PROLIA, XGEVA, and EYLEA.

• Achieved approximately $600 million in revenue and $140 million EBITDA last year, guiding to $650–$700 million revenue and $180–$200 million EBITDA this year.

• Maintains a pipeline of 32 assets, with five commercialized and several more in late-stage development, emphasizing limited competition launches.

• Six of the next eight to nine launches are expected to face limited competition, providing a first-to-market advantage.

Regulatory and manufacturing updates

• Addressed FDA Form 483 observations from a 2023 inspection, impacting three pipeline programs with CRLs; remediation efforts included production slowdowns and process improvements.

• Plans to resubmit BLAs in June, targeting approvals by December 2025, with readiness for potential re-inspection.

• Recent surprise FDA inspection resulted in manageable observations, not expected to delay resubmission.

• Commercial supply of Humira and Stelara to the U.S. remains unaffected by facility observations.

Market and competitive landscape

• SIMPONI is prioritized for launch due to favorable market exclusivity dynamics, with EYLEA and PROLIA following.

• Partnership with Teva supports commercial execution, and EYLEA launch timing is unaffected by regulatory delays.

• Announced partnership with FUJIFILM Biotech to expand manufacturing capacity in the U.S. and U.K., aiming for operational readiness in the second half of next year.

• Tech transfer to new facilities focuses on currently commercial products, with future capacity supporting pipeline growth.